Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-l

Hepato-Gastroenterology

Volumn 62, Issue 138, 2015, Pages 478-484

  Kurihara, Tatsuya ^a   Kogo, Mari ^a   Ishii, Masakazu ^a   Yoneyama, Keiichiro ^a   Kitamura, Katsuya ^a   Shimada, Ken ^a   Shimizu, Shunichi ^a   Yoshida, Hitoshi ^a   Kiuchi, Yuji ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Gemcitabine; S l; Unresectable pancreatic cancer

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; SODIUM; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VERY ELDERLY; ANALOGS AND DERIVATIVES; CANCER STAGING; CLASSIFICATION; DECISION SUPPORT SYSTEM; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PANCREATIC NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DECISION SUPPORT TECHNIQUES; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUTROPHILS; OXONIC ACID; PANCREATIC NEOPLASMS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928572322     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge141017     Document Type: Article

References (35)

1. Jemal A, Bray F, Center M.M., et al: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 1996; 78: 654-663.
3. Bramhall SRI, Rosemurgy A, Brown P.D., et al: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-3455.
4. Berlin JD, Catalano P, Thomas I.P., et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
5. Bramhall SR, Schultz J, Nemunaitis J., et al: A double-blind placebo-controlled randomized study coparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87:161-167.
6. Heinemann V, Quietzsch D, Gieseler F., et al: A phase III trial comparing gemcitabine plus cisplatine compared with gemcitabine alone in advanced pancreatic adenocarcinoma. J Clin Oncol 2006; 24: 3946-3952.
7. Moore JM, Hamm J, Dancey J., et al: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 2003; 21: 3296-3302.
8. Rocha Lima CMS, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783.
9. Van Cutsem E., van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22:1430-1348.
10. Abou-Alfa G.K., Letorneau R, Harker G., et al: A randomised phase III trial of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24:4441-4447.
11. Oettle H, Richards D, Ramanathan R.K., et al: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 10:1639-1645.
12. Louvet C, Labianca R, Hammel G., et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Cin Oncol 2005; 23: 3509-3516.
13. Reni M, Cordio S, Milandri C., et al: Gemcitabine versus cisplatin, epirubicin, fluorouracil and gemcitabine in advanced pancreatic cancer: a randomised controlled multicenter phase III trial. Lancet Oncol 2005; 6: 369-376.
14. Moore MJ, Goldstein D, Hamm J., et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol; 25:1960-1966.
15. Cunningham D, Chau I, Stocken D.D., et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518.
16. Ueno H, Ioka T, Ikeda M., et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-1648.
17. Yamaguchi K, Okusaka T, Shimizu K., et al: EBM-based Clinical Guidelines for Pancreatic Cancer (2013) Issued by the Japan Pancreas Society: A Synopsis Jpn J Clin Oncol 2014.
18. Ziske C, Schlie C, Gorschlüter M, et al: Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-1417.
19. Ikeda M, Okada S, Tokuuye K., et al: Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001; 91: 490-495.
20. Ishii H, Okada S, Nose H., et al: Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996; 12: 267-271.
21. Ueno H, Okada S, Okusaka T., et al: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59: 296-301.
22. Tanaka T, Ikeda M, Okusaka T., et al: Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008; 38: 755-761.
23. Sawaki A, Kanemitsu Y, Mizuno N., et al: Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol 2008; 23: 1292-1297.
24. Maréchal R., Demols A, Gay F., et al: Prognostic factors and prognostic index for chemonai've and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology 2007; 73:41-51.
25. Cubiella J, Castells A, Fondevilla C., et al: Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol 1999; 94:1271-1278.
26. Morizane C, Okusaka T, Morita S., et al: Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas 2011; 40: 415-21.
27. Kim JG, Ryoo BY, Park Y.H., et al: Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2008; 61: 301-307.
28. Jeremic B, Milicic B, Dagovic A., et al: Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol 2003; 129:114-122.
29. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867.
30. Helmut S, Oka M, Thomas B., et al: Differential Response of Primary and Metastatic Melanomas to Neutrophils Attracted by IL-8. Int J Cancer 2003; 103: 335-343.
31. Peter S, Jess DS, Ben JZP, et al: Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001; 189:197-206.
32. Atzpodien J, Royston P, Wandert T., et al: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88: 348-353.
33. Négrier S., Escudier B, Gomez F., et al: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13: 1460-1468.
34. Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24:1997-2005
35. Yamanaka T, Matsumoto S, Teramukai S., et al: The baseline ratio of neutrophils with patient prognosis in advanced gastric Cancer. Oncology 2007; 73: 215-220.